Semaglutide improves maximal walking distance in people with symptomatic PAD and Type 2 diabetes
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the first-of-its kind trial to…